We are pleased to announce that a collaborative research paper, led by our intern Emi Miyashita as first author and our CTO Richard Kaoru Komatsu as corresponding author, has been published in Nature Communications.
This study was conducted in collaboration with Center for iPS Cell Research and Application, Kyoto University and Institute of Multidisciplinary Research for Advanced Materials, Tohoku University.
The paper is titled:
“Systematic identification of variant-specific RNA structure–small molecule interactions exemplified by RNA G-quadruplexes.”
In this work, the research team developed a novel technology called BIVID-MaP, which enables large-scale detection of RNA-binding motifs. Using this method, the team successfully identified variant-specific compound binding at single-nucleotide resolution, representing a significant advancement in the analysis of RNA–small molecule interactions.
The paper has been published in Nature Communications.
Title: Systematic identification of variant-specific RNA structure-small molecule interactions exemplified by RNA G-quadruplexes
Authors: Emi Miyashita*, Kazumitsu Onizuka, Yutong Chen, Hiroki Yoshida, Hina Hatayama, Shunya Ishikawa, Peijie Yan, Takahito Hasegawa, Mamiko Ozawa, Kaho Maeta, Fumi Nagatsugi, Hirohide Saito & Kaoru R. Komatsu**
*First Author, **Corresponding Author
- Click here for more information(Center for iPS Cell Research and Application, Kyoto University )
- Click here for more information (Nature Communications)
About xFOREST Therapeutics
xFOREST Therapeutics Co., Ltd. is a Kyoto-based biotechnology company engaged in the research and development of RNA-targeted small-molecule medicines. Building on its proprietary RNA structure analysis technology, xFOREST discovers selective small molecules for RNA targets that protein-first discovery cannot reach, and advances them into drug programs with partners.